Drug updated on 4/17/2024
| Dosage Form | Injection (subcutaneous; 94.5 mg/0.5 mL) |
| Drug Class | HAO1-directed small interfering ribonucleic acids |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Oxlumo (lumasiran) Prescribing Information. | 2022 | Alnylam Pharmaceuticals, Inc., Cambridge, MA |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Clinical, pharmacoeconomic and ethics combined report. | 2023 | CADTH |
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Clinical practice recommendations for primary hyperoxaluria: an expert consensus statement from ERKNet and OxalEurope. | 2023 | Nature Reviews Nephrology |